Ascletis Pharma-B (01672.HK): New Drug Clinical Trial Application for Oral Small-Molecule Selective Amylin Receptor Agonist ASC39 for Obesity Treatment Has Been Submitted to the U.S. FDA

Zhitong Finance APP News, Ascletis Pharma-B (01672.HK) announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ASC39 oral tablets. ASC39 oral tablets are an oral small-molecule selective amylin receptor agonist for the treatment of obesity.